AQR Capital Management
VYGR icon

AQR Capital Management’s Voyager Therapeutics VYGR Stock Holding History

AQR Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
356,109
+123,428
+53% +$468K ﹤0.01% 2883
2026
Q1 		$898K Buy
232,681
+72,644
+45% +$286K ﹤0.01% 2826
2025
Q4 		$629K Sell
160,037
-16,179
-9% -$71.6K ﹤0.01% 2794
2025
Q3 		$823K Sell
176,216
-106,990
-38% -$387K ﹤0.01% 2542
2025
Q2 		$881K Sell
283,206
-212,054
-43% -$684K ﹤0.01% 2288
2025
Q1 		$1.67M Buy
495,260
+317,927
+179% +$1.49M ﹤0.01% 1709
2024
Q4 		$1.01M Sell
177,333
-71,290
-29% -$460K ﹤0.01% 1884
2024
Q3 		$1.45M Sell
248,623
-253,752
-51% -$1.84M ﹤0.01% 1655
2024
Q2 		$3.97M Sell
502,375
-291,259
-37% -$2.44M 0.01% 1121
2024
Q1 		$7.39M Buy
793,634
+154,347
+24% +$1.3M 0.01% 828
2023
Q4 		$5.4M Buy
639,287
+440,465
+222% +$3.2M 0.01% 915
2023
Q3 		$1.54M Buy
+198,822
New +$1.82M ﹤0.01% 1435
2021
Q3 		– Sell
-166,330
Closed -$687K – 2339
2021
Q2 		$687K Sell
166,330
-196,108
-54% -$889K ﹤0.01% 1754
2021
Q1 		$1.71M Buy
362,438
+195,083
+117% +$1.33M ﹤0.01% 1291
2020
Q4 		$1.2M Buy
167,355
+141,435
+546% +$1.36M ﹤0.01% 1426
2020
Q3 		$277K Sell
25,920
-25,644
-50% -$301K ﹤0.01% 1951
2020
Q2 		$651K Sell
51,564
-6,966
-12% -$81K ﹤0.01% 1654
2020
Q1 		$536K Sell
58,530
-11,926
-17% -$137K ﹤0.01% 1561
2019
Q4 		$983K Sell
70,456
-7,449
-10% -$108K ﹤0.01% 1521
2019
Q3 		$1.34M Buy
77,905
+57,299
+278% +$1.2M ﹤0.01% 1427
2019
Q2 		$561K Sell
20,606
-4,059
-16% -$92.9K ﹤0.01% 1695
2019
Q1 		$472K Sell
24,665
-24,924
-50% -$325K ﹤0.01% 1826
2018
Q4 		$466K Buy
49,589
+30,608
+161% +$393K ﹤0.01% 1811
2018
Q3 		$359K Sell
18,981
-4,346
-19% -$83.4K ﹤0.01% 2057
2018
Q2 		$456K Buy
+23,327
New +$461K ﹤0.01% 2006

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AQR Capital Management's VYGR Position: Q2 2026 in Review

AQR Capital Management increased its Voyager Therapeutics (VYGR) stake by 53% in Q2 2026, buying an estimated $468K and bringing the position to 356,109 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2883.

AQR Capital Management first reported a position in VYGR in Q2 2018 and has held it in 25 quarters since. The position peaked at $7.39M in Q1 2024. 135 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • AQR Capital Management held 356,109 shares of Voyager Therapeutics worth $1.25M as of Q2 2026.
  • AQR Capital Management bought 123,428 Voyager Therapeutics shares in Q2 2026, an estimated $468K.
  • Voyager Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2883 holding.
  • AQR Capital Management first reported a position in Voyager Therapeutics in Q2 2018 and has held it in 25 quarters since.
  • AQR Capital Management's Voyager Therapeutics position peaked at $7.39M in Q1 2024.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.